Kangyueda (stapokibart) / CSPC Pharma, Keymed Biosciences - LARVOL DELTA

Stapokibart as Add-on Therapy for Moderate-to-Severe Alopecia Areata With Atopic Background During Upadacitinib Maintenance (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Stapokibart for Facial-Predominant AD-Like Dermatoses: A Retrospective Real-World Case Series Highlighting Response Heterogeneity. (PubMed, Clin Cosmet Investig Dermatol) - "In this small case series, rapid improvement was observed in all three patients with a well-supported facial-predominant AD phenotype, whereas atypical or incompletely characterized eruptions showed greater diagnostic complexity and variable outcomes. These preliminary observations support further investigation of stapokibart in facial-predominant AD while underscoring the need for careful phenotyping before IL-4Rα blockade."

Heterogeneity • Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Dermatomyositis • Immunology • Inflammation • Myositis • Pruritus • Rosacea

A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Checkpoint inhibition • New P2 trial • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review. (PubMed, Front Surg) - "Although dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, depemokimab, and stapokibart have demonstrated substantial clinical efficacy, the optimal duration and maintenance strategy for biologic therapy remain uncertain...However, standardized tapering protocols and high-quality randomized controlled trials are required before routine implementation. Future research should focus on biomarker-guided patient selection, long-term clinical outcomes, and the cost-effectiveness of biologic dose optimization."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Response-Guided Stratified Exploratory Study of Sequential Therapy with Mepolizumab and Stapokibart for CRSwNP Complicated with SEA (ChiCTR) - P4 | N=180 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New P4 trial • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Long-Term Safety of Anti-IL-4Rα Stapokibart in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: A Phase II, Multicenter, Open-Label, Single-Arm Study (EADV 2026) - No abstract available

Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world outcomes of stapokibart-based combination therapy in bullous pemphigoid: a single-center retrospective cohort (EADV 2026) - No abstract available

Combination therapy • Real-world • Real-world evidence • Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Two cases of refractory hyperkeratotic eczema on feet were successfully treated with stapokibart (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatology • Immunology

A Real-World Short-Term Study on the Efficacy and Safety of Stapokibart in Middle-Aged and Elderly Patients with Moderate-to-Severe Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and Safety of Anti-IL-4Rα Stapokibart for Chinese Adults With Moderate-to-Severe Prurigo Nodularis: A Phase 3 Randomized Clinical Trial (EADV 2026) - No abstract available

Clinical • P3 data • Immunology • Prurigo Nodularis

Long-Term Efficacy of Extending Dosing Interval of Stapokibart (Anti-IL-4Rα) in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: 52-Week Results of a Phase II, Multicenter, Open-Label, Single-Arm Study (EADV 2026) - No abstract available

Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Faster disease control and corticosteroid sparing with short-course stapokibart in moderate-to-severe bullous pemphigoid: a prospective study (EADV 2026) - No abstract available

Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Stapokibart for Treatment of Immune Checkpoint Inhibitor-induced Bullous Pemphigoid (EADV 2026) - No abstract available

Checkpoint inhibition • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Oncology

Long-Term Efficacy and Safety of Anti-IL-4Rα Stapokibart for Adolescents With Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension Study of a Phase 3 Clinical Trial (EADV 2026) - No abstract available

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps (ERS 2026) - "This presentation will review whether stapokibart, a novel anti-interleukin-4Rα monoclonal antibody, decreases nasal polyps and reduces symptoms of nasal congestion among patients with severe chronic rhinosinusitis with nasal polyps, highlighting the clinical trial published by the speaker."

Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

SESSION 316 Highlights from JAMA (ERS 2026) - "To provide information about new diagnostic approaches for COPD; provide evidence from the Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps (CROWN-2) randomised controlled trial; to provide information about a patient-directed approach to lung cancer screening. Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory critical care physician, Physician in Pulmonary Training"

Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Lung Cancer • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Solid Tumor

Endoscopic Ethmoid Infundibulum Expansion Surgery (EEIES) Combined with Stapokibart in the Treatment of Crswnp (AAO-HNSF 2026) - P=N/A | "EEIES combined with biologics achieves comparable efficacy to conventional ESS with biologics. Stapokibart effectively suppresses type 2 inflammation and restores mucosal homeostasis, while EEIES targets meatal hypoxia relief—not ostial widening. Effective sinus drainage depends on mucociliary function, not ostial width, making EEIES a biologically rational approach for long-term disease control in CRSwNP."

Surgery • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - P3 | N=136 | Recruiting | Sponsor: Chengdu Kangnuoxing Biopharma,Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Allergic Rhinitis • Immunology • Inflammation

IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies. (PubMed, Front Immunol) - "On the other hand, it has also been observed that blocking Th2-related pathways, such as IL-4/IL-13, IL-5, or IL-31, paradoxically causes PPP, highlighting the bidirectional and context-dependent significance of Th2 signaling in disease pathogenesis. Together with clinical characteristics like excessive pruritus, tissue-level Th2 activation may offer useful indicators to direct precision treatment in this diverse illness."

Journal • Review • Dermatology • Eosinophilia • Immunology • Ophthalmology • Pruritus • Psoriasis • CD4 • IL13 • IL17A • IL23A • IL4 • IL5 • STAT6

A short-course and season-oriented Stapokibart strategy for moderate-to-severe seasonal allergic rhinitis: Real-world evidence from Northern China. (PubMed, World Allergy Organ J) - "A two-dose, season-oriented Stapokibart regimen achieved rapid and durable symptom control with favorable safety in real-world SAR. This pragmatic strategy may represent a practical biologic approach aligned with seasonal disease dynamics."

HEOR • Journal • Real-world evidence • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=263 | Completed | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Nov 2025 | Trial primary completion date: Mar 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comment on 'Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort': towards controlled comparisons, neurological profiling, and long-term follow-up: reply from authors. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Real-world evidence • Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Highlights from JAAD Case Reports: October 2026. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Treatment of allergic rhinitis in the biologics era (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi) - "Clinical studies have demonstrated that omalizumab, dupilumab, and stapokibart are effective in treating seasonal AR. In 2025, stapokibart was approved for the treatment of moderate-to-severe seasonal AR in adults, becoming the world's first targeted IL-4Rα monoclonal antibody for AR therapy. This article systematically reviews the history and efficacy of biologics in the treatment of AR, as well as the development of domestic biologics, aiming to emphasize the importance of their clinical application strategies."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation

Efficacy Evaluation and Mechanistic Study of Stapokibart in the Treatment of Moderate-to-Severe Bullous Pemphigoid (ChiCTR) - P=N/A | N=100 | Recruiting | Sponsor: Wuhan Hospital of Integrated Traditional Chinese and Western Medicine (Wuhan First Hospital); Traditional Chinese and Western Medicine Hospital of Wuh

New trial • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology